Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

Stefania Piconi, Serena Parisotto, Giuliano Rizzardini, Simone Passerini, Paola Meraviglia, Monica Schiavini, Fosca Niero, Mara Biasin, Paolo Bonfanti, Elena Delfina Ricci, Daria Trabattoni, Mario Clerici

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: HIV-infected patients have a greater burden of sub-clinical and clinical atherosclerotic disease compared to the general population. The primary objective of this study was to compare the relative roles of inflammation, endothelial alterations, and metabolic factors in the induction and maintenance of atherosclerosis in antiretroviral therapy (ART)-treated or ART-naive patients. DESIGN: Cross-sectional study; 79 HIV-infected patients (55 ART-treated and 24 naive individuals) were consecutively enrolled. In both groups, nearly 50% of the individuals had a high cardiovascular risk (Framingham value >20%). METHODS: Echo-Doppler [intima-media thickness (IMT)], inflammatory, thrombophilic, endothelial, metabolic indexes, and cholesterol efflux molecules were evaluated. Multivariate analysis adjusted for age, CD4 nadir, BMI, and Framingham's score were used to analyze the results. RESULTS: A complex pathogenesis drives atherogenesis in HIV infection. Thus, whereas inflammation could be responsible for this process in ART-naive individuals, metabolic factors [low-density lipoprotein (LDL), apolipoprotein B (ApoB), lipoprotein A] seem to play a more prevalent role in ART-treated patients. Notably, ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux, which is inhibited by Nef, is up-regulated in ART-treated individuals. CONCLUSION: Atherosclerosis in HIV infection results from the interaction of multiple factors: an inflammatory and HIV-driven disease could prevail in the absence of therapy; metabolic, non-inflammatory causes may be more important in patients undergoing therapy. Approaches to atherosclerotic disease in HIV infection should consider these differences.

Original languageEnglish
Pages (from-to)381-389
Number of pages9
JournalAIDS (London, England)
Volume27
Issue number3
DOIs
Publication statusPublished - Jan 28 2013

Fingerprint

Atherosclerosis
HIV
HIV Infections
Therapeutics
ATP Binding Cassette Transporter 1
Cholesterol
Inflammation
Apolipoproteins B
LDL Lipoproteins
Lipoproteins
Multivariate Analysis
Cross-Sectional Studies
Maintenance
Population
Proteins

Keywords

  • ABCA-1
  • ART
  • atherosclerosis
  • HIV
  • immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. / Piconi, Stefania; Parisotto, Serena; Rizzardini, Giuliano; Passerini, Simone; Meraviglia, Paola; Schiavini, Monica; Niero, Fosca; Biasin, Mara; Bonfanti, Paolo; Ricci, Elena Delfina; Trabattoni, Daria; Clerici, Mario.

In: AIDS (London, England), Vol. 27, No. 3, 28.01.2013, p. 381-389.

Research output: Contribution to journalArticle

Piconi, S, Parisotto, S, Rizzardini, G, Passerini, S, Meraviglia, P, Schiavini, M, Niero, F, Biasin, M, Bonfanti, P, Ricci, ED, Trabattoni, D & Clerici, M 2013, 'Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals', AIDS (London, England), vol. 27, no. 3, pp. 381-389. https://doi.org/10.1097/QAD.0b013e32835abcc9
Piconi, Stefania ; Parisotto, Serena ; Rizzardini, Giuliano ; Passerini, Simone ; Meraviglia, Paola ; Schiavini, Monica ; Niero, Fosca ; Biasin, Mara ; Bonfanti, Paolo ; Ricci, Elena Delfina ; Trabattoni, Daria ; Clerici, Mario. / Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. In: AIDS (London, England). 2013 ; Vol. 27, No. 3. pp. 381-389.
@article{64f807950d3b4bc19924d951a9279443,
title = "Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals",
abstract = "OBJECTIVES: HIV-infected patients have a greater burden of sub-clinical and clinical atherosclerotic disease compared to the general population. The primary objective of this study was to compare the relative roles of inflammation, endothelial alterations, and metabolic factors in the induction and maintenance of atherosclerosis in antiretroviral therapy (ART)-treated or ART-naive patients. DESIGN: Cross-sectional study; 79 HIV-infected patients (55 ART-treated and 24 naive individuals) were consecutively enrolled. In both groups, nearly 50{\%} of the individuals had a high cardiovascular risk (Framingham value >20{\%}). METHODS: Echo-Doppler [intima-media thickness (IMT)], inflammatory, thrombophilic, endothelial, metabolic indexes, and cholesterol efflux molecules were evaluated. Multivariate analysis adjusted for age, CD4 nadir, BMI, and Framingham's score were used to analyze the results. RESULTS: A complex pathogenesis drives atherogenesis in HIV infection. Thus, whereas inflammation could be responsible for this process in ART-naive individuals, metabolic factors [low-density lipoprotein (LDL), apolipoprotein B (ApoB), lipoprotein A] seem to play a more prevalent role in ART-treated patients. Notably, ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux, which is inhibited by Nef, is up-regulated in ART-treated individuals. CONCLUSION: Atherosclerosis in HIV infection results from the interaction of multiple factors: an inflammatory and HIV-driven disease could prevail in the absence of therapy; metabolic, non-inflammatory causes may be more important in patients undergoing therapy. Approaches to atherosclerotic disease in HIV infection should consider these differences.",
keywords = "ABCA-1, ART, atherosclerosis, HIV, immunology",
author = "Stefania Piconi and Serena Parisotto and Giuliano Rizzardini and Simone Passerini and Paola Meraviglia and Monica Schiavini and Fosca Niero and Mara Biasin and Paolo Bonfanti and Ricci, {Elena Delfina} and Daria Trabattoni and Mario Clerici",
year = "2013",
month = "1",
day = "28",
doi = "10.1097/QAD.0b013e32835abcc9",
language = "English",
volume = "27",
pages = "381--389",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

AU - Piconi, Stefania

AU - Parisotto, Serena

AU - Rizzardini, Giuliano

AU - Passerini, Simone

AU - Meraviglia, Paola

AU - Schiavini, Monica

AU - Niero, Fosca

AU - Biasin, Mara

AU - Bonfanti, Paolo

AU - Ricci, Elena Delfina

AU - Trabattoni, Daria

AU - Clerici, Mario

PY - 2013/1/28

Y1 - 2013/1/28

N2 - OBJECTIVES: HIV-infected patients have a greater burden of sub-clinical and clinical atherosclerotic disease compared to the general population. The primary objective of this study was to compare the relative roles of inflammation, endothelial alterations, and metabolic factors in the induction and maintenance of atherosclerosis in antiretroviral therapy (ART)-treated or ART-naive patients. DESIGN: Cross-sectional study; 79 HIV-infected patients (55 ART-treated and 24 naive individuals) were consecutively enrolled. In both groups, nearly 50% of the individuals had a high cardiovascular risk (Framingham value >20%). METHODS: Echo-Doppler [intima-media thickness (IMT)], inflammatory, thrombophilic, endothelial, metabolic indexes, and cholesterol efflux molecules were evaluated. Multivariate analysis adjusted for age, CD4 nadir, BMI, and Framingham's score were used to analyze the results. RESULTS: A complex pathogenesis drives atherogenesis in HIV infection. Thus, whereas inflammation could be responsible for this process in ART-naive individuals, metabolic factors [low-density lipoprotein (LDL), apolipoprotein B (ApoB), lipoprotein A] seem to play a more prevalent role in ART-treated patients. Notably, ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux, which is inhibited by Nef, is up-regulated in ART-treated individuals. CONCLUSION: Atherosclerosis in HIV infection results from the interaction of multiple factors: an inflammatory and HIV-driven disease could prevail in the absence of therapy; metabolic, non-inflammatory causes may be more important in patients undergoing therapy. Approaches to atherosclerotic disease in HIV infection should consider these differences.

AB - OBJECTIVES: HIV-infected patients have a greater burden of sub-clinical and clinical atherosclerotic disease compared to the general population. The primary objective of this study was to compare the relative roles of inflammation, endothelial alterations, and metabolic factors in the induction and maintenance of atherosclerosis in antiretroviral therapy (ART)-treated or ART-naive patients. DESIGN: Cross-sectional study; 79 HIV-infected patients (55 ART-treated and 24 naive individuals) were consecutively enrolled. In both groups, nearly 50% of the individuals had a high cardiovascular risk (Framingham value >20%). METHODS: Echo-Doppler [intima-media thickness (IMT)], inflammatory, thrombophilic, endothelial, metabolic indexes, and cholesterol efflux molecules were evaluated. Multivariate analysis adjusted for age, CD4 nadir, BMI, and Framingham's score were used to analyze the results. RESULTS: A complex pathogenesis drives atherogenesis in HIV infection. Thus, whereas inflammation could be responsible for this process in ART-naive individuals, metabolic factors [low-density lipoprotein (LDL), apolipoprotein B (ApoB), lipoprotein A] seem to play a more prevalent role in ART-treated patients. Notably, ABCA-1, an ATP-binding transporter cassette protein involved in cholesterol efflux, which is inhibited by Nef, is up-regulated in ART-treated individuals. CONCLUSION: Atherosclerosis in HIV infection results from the interaction of multiple factors: an inflammatory and HIV-driven disease could prevail in the absence of therapy; metabolic, non-inflammatory causes may be more important in patients undergoing therapy. Approaches to atherosclerotic disease in HIV infection should consider these differences.

KW - ABCA-1

KW - ART

KW - atherosclerosis

KW - HIV

KW - immunology

UR - http://www.scopus.com/inward/record.url?scp=84872326711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872326711&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835abcc9

DO - 10.1097/QAD.0b013e32835abcc9

M3 - Article

C2 - 23079800

AN - SCOPUS:84872326711

VL - 27

SP - 381

EP - 389

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -